MDM2 inhibitors for pancreatic cancer therapy

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 6, 2010, Pages 518-526

  Azmi, A S ^a   Philip, P A ^a   Almhanna, K ^a   Beck, F W ^a   Kafri, Z K ^a   Sarkar, F H ^a   Mohammad, R M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

MDM2 and p53; Pancreatic cancer; Small molecule inhibitors

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; APR 246; ARABINOSIDE; BENZODIAZEPINE DERIVATIVE; CHLORAMBUCIL; CISPLATIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTOSINE; DACTINOMYCIN; DOXORUBICIN; FLUDARABINE; GEMCITABINE; LEPTOMYCIN B; MI 219; MI 319; NUTLIN 3; OXALIPLATIN; PROTEIN MDM2; PROTEIN P53; TDP 665759; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; HUMAN; MOLECULAR MECHANICS; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RHABDOMYOSARCOMA; WILD TYPE;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77953702026     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955710791384054     Document Type: Article

References (87)

1. Somasundaram, K. Tumor suppressor p53: regulation and function. Front. Biosci., 2000, 5, D424-D437.
2. Wiman, K.G. P53: emergency brake and target for cancer therapy. Exp. Cell Res., 1997, 237, 14-18.
3. He, G.; Siddik, Z.H.; Huang, Z.; Wang, R.; Koomen, J.; Kobayashi, R.; Khokhar, A.R.; Kuang, J. Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene, 2005, 24, 2929-2943.
4. Bartek, J.; Lukas, J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett., 2001, 490, 117-122.
5. Bringold, F.; Serrano, M. Tumor suppressors and oncogenes in cellular senescence. Exp. Gerontol., 2000, 35, 317-329.
6. Kastan, M.B. Wild-type p53: tumors can't stand it. Cell, 2007, 128, 837-840.
7. Campling, B.G.; el-Deiry, W.S. Clinical implications of p53 mutations in lung cancer. Methods Mol. Med., 2003, 75, 53-77.
8. Bosari, S.; Viale, G. The clinical significance of p53 aberrations in human tumours. Virchows Arch., 1995, 427, 229-241.
9. Brown, C.J.; Lain, S.; Verma, C.S.; Fersht, A.R.; Lane, D.P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer, 2009, 9, 862-873.
10. Fakharzadeh, S.S.; Rosenblum-Vos, L.; Murphy, M.; Hoffman, E.K.; George, D.L. Structure and organization of amplified DNA on double minutes containing the mdm2 oncogene. Genomics, 1993, 15, 283-290.
11. Fakharzadeh, S.S.; Trusko, S.P.; George, D.L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J., 1991, 10, 1565-1569.
12. Oliner, J.D. Discerning the function of p53 by examining its molecular interactions. Bioessays, 1993, 15, 703-707.
13. Oliner, J.D.; Pietenpol, J.A.; Thiagalingam, S.; Gyuris, J.; Kinzler, K.W.; Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 1993, 362, 857-860.
14. Momand, J.; Jung, D.; Wilczynski, S.; Niland, J. The MDM2 gene amplification database. Nucleic Acids Res., 1998, 26, 3453-3459.
15. Momand, J.; Zambetti, G.P. Mdm-2: big brother of p53. J. Cell Biochem., 1997, 64, 343-352.
16. Momand, J.; Zambetti, G.P.; Olson, D.C.; George, D.; Levine, A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 1992, 69, 1237-1245.
17. Chen, J.; Marechal, V.; Levine, A.J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol., 1993, 13, 4107-4114.
18. Freedman, D.A.; Levine, A.J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell Biol., 1998, 18, 7288-7293.
19. Freedman, D.A.; Epstein, C.B.; Roth, J.C.; Levine, A.J. A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol. Med., 1997, 3, 248-259.
20. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Mdm2 promotes the rapid degradation of p53. Nature, 1997, 387, 296-309.
21. Kastan, M.B. Wild-type p53: tumors can't stand it. Cell, 2007, 128, 837-840.
22. Mancini, F.; Conza, G.D.; Moretti, F. MDM4 (MDMX) and its Transcript Variants. Curr. Genomics, 2009, 10, 42-50.
23. Barboza, J.A.; Iwakuma, T.; Terzian, T.; El-Naggar, A.K.; Lozano, G. Mdm2 and Mdm4 loss regulates distinct p53 activities. Mol. Cancer Res., 2008, 6, 947-954.
24. Matheu, A.; Maraver, A.; Serrano, M. The Arf/p53 pathway in cancer and aging. Cancer Res., 2008, 68, 6031-6034.
25. Vassilev, L.T. MDM2 inhibitors for cancer therapy. Trends Mol. Med., 2007, 13, 23-31.
26. Wiman, K.G. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. Adv. Cancer Res., 2007, 97, 321-338.
27. Wiman, K.G. New p53-based anti-cancer therapeutic strategies. Med. Oncol., 1998, 15, 222-228.
28. Lehman, J.A.; Eitel, J.A.; Batuello, C.N.; Mayo, L.D. Therapeutic considerations for Mdm2: not just a one trick pony. Expert Opin. Drug Discov., 2008, 3, 1309-1321.
29. Do, T.N.; Ucisik-Akkaya, E.; Davis, C.F.; Morrison, B.A.; Dorak, M.T. TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility. Cancer Genet. Cytogenet., 2009, 195, 31-36.
30. Assmann, G.; Voswinkel, J.; Mueller, M.; Bittenbring, J.; Koenig, J.; Menzel, A.; Pfreundschuh, M.; Roemer, K.; Melchers, I. Association of rheumatoid arthritis with Mdm2 SNP309 and genetic evidence for an allele-specific interaction between MDM2 and p53 P72R variants: a case control study. Clin. Exp. Rheumatol., 2009, 27, 615-619.
31. Shinohara, A.; Sakano, S.; Hinoda, Y.; Nishijima, J.; Kawai, Y.; Misumi, T.; Nagao, K.; Hara, T.; Matsuyama, H. Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy. Cancer Sci., 2009, 100(12), 2376-2382.
32. Grochola, L.F.; Muller, T.H.; Bond, G.L.; Taubert, H.; Udelnow, A.; Wurl, P. MDM2 SNP309 Associates With Accelerated Pancreatic Adenocarcinoma Formation. Pancreas, 2010, 39, 76-80.
33. Lang, A.; Palmeback, W.P.; Wingren, S. The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer. Oncol. Rep., 2009, 22, 575-579.
34. Economopoulos, K.P.; Sergentanis, T.N. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res. Treat., 2010, 120(1), 211-216.
35. Perfumo, C.; Parodi, S.; Mazzocco, K.; Defferrari, R.; Inga, A.; Scarra, G.B.; Ghiorzo, P.; Haupt, R.; Tonini, G.P.; Fronza, G. MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma. Pediatr. Blood Cancer, 2009, 53, 576-583.
36. Mendrysa, S.M.; McElwee, M.K.; Michalowski, J.; O'Leary, K.A.; Young, K.M.; Perry, M.E. mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol. Cell Biol., 2003, 23, 462-472.
37. Vassilev, L.T.; Vu, B.T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 2004, 303, 844-848.
38. Shangary, S.; Wang, S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu. Rev. Pharmacol. Toxicol., 2009, 49, 223-241.
39. Hedstrom, E.; Eriksson, S.; Zawacka-Pankau, J.; Arner, E.S.; Selivanova, G. p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA. Cell Cycle, 2009, 8, 3576-3583.
40. Vassilev, L.T. MDM2 inhibitors for cancer therapy. Trends Mol. Med., 2007, 13, 23-31.
41. Vassilev, L.T. p53 Activation by small molecules: application in oncology. J. Med. Chem., 2005, 48, 4491-4499.
42. Vassilev, L.T. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle, 2004, 3, 419-421.
43. Vassilev, L.T.; Vu, B.T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 2004, 303, 844-848.
44. Canner, J.A.; Sobo, M.; Ball, S.; Hutzen, B.; De Angelis, S.; Willis, W.; Studebaker, A.W.; Ding, K.; Wang, S.; Yang, D.; Lin, J. MI- 63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br. J. Cancer, 2009, 101, 774-781.
45. Shangary, S.; Qin, D.; McEachern, D.; Liu, M.; Miller, R.S.; Qiu, S.; Nikolovska-Coleska, Z.; Ding, K.; Wang, G.; Chen, J.; Bernard, D.; Zhang, J.; Lu, Y.; Gu, Q.; Shah, R.B.; Pienta, K.J.; Ling, X.; Kang, S.; Guo, M.; Sun, Y.; Yang, D.; Wang, S. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. U. S. A, 2008, 105, 3933-3938.
46. Fotouhi, N.; Graves, B. Small molecule inhibitors of p53/MDM2 interaction. Curr. Top. Med. Chem., 2005, 5, 159-165.
47. Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Wang, G.; Qiu, S.; Shangary, S.; Gao, W.; Qin, D.; Stuckey, J.; Krajewski, K.; Roller, P.P.; Wang, S. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J. Med. Chem., 2006, 49, 3432-3435.
48. Shangary, S.; Qin, D.; McEachern, D.; Liu, M.; Miller, R.S.; Qiu, S.; Nikolovska-Coleska, Z.; Ding, K.; Wang, G.; Chen, J.; Bernard, D.; Zhang, J.; Lu, Y.; Gu, Q.; Shah, R.B.; Pienta, K.J.; Ling, X.; Kang, S.; Guo, M.; Sun, Y.; Yang, D.; Wang, S. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. U. S. A, 2008, 105, 3933-3938.
49. Patel, S.; Player, M.R. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert. Opin. Investig. Drugs, 2008, 17, 1865-1882.
50. Koblish, H.K.; Zhao, S.; Franks, C.F.; Donatelli, R.R.; Tominovich, R.M.; LaFrance, L.V.; Leonard, K.A.; Gushue, J.M.; Parks, D.J.; Calvo, R.R.; Milkiewicz, K.L.; Marugan, J.J.; Raboisson, P.; Cummings, M.D.; Grasberger, B.L.; Johnson, D.L.; Lu, T.; Molloy, C.J.; Maroney, A.C. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol. Cancer Ther., 2006, 5, 160-169.
51. Lee, J.T.; Gu, W. The multiple levels of regulation by p53 ubiquitination. Cell Death. Differ., 2010, 17, 86-92.
52. Kruse, J.P.; Gu, W. Modes of p53 regulation. Cell, 2009, 137, 609-22.
53. Halaby, M.J.; Yang, D.Q. p53 translational control: a new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics. Gene, 2007, 395, 1-7.
54. Schumacher, B.; Gartner, A. Translational regulation of p53 as a potential tumor therapy target. Future Oncol., 2006, 2, 145-153.
55. Chuikov, S.; Kurash, J.K.; Wilson, J.R.; Xiao, B.; Justin, N.; Ivanov, G.S.; McKinney, K.; Tempst, P.; Prives, C.; Gamblin, S.J.; Barlev, N.A.; Reinberg, D. Regulation of p53 activity through lysine methylation. Nature, 2004, 432, 353-360.
56. Haupt, Y. p53 Regulation: a family affair. Cell Cycle, 2004, 3, 884-885.
57. Brooks, C.L.; Gu, W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol., 2003, 15, 164-171.
58. Wiederschain, D.; Gu, J.; Yuan, Z.M. Evidence for a distinct inhibitory factor in the regulation of p53 functional activity. J. Biol. Chem., 2001, 276, 27999-28005.
59. Craig, A.L.; Burch, L.; Vojtesek, B.; Mikutowska, J.; Thompson, A.; Hupp, T.R. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem. J., 1999, 342 (Pt 1), 133-141.
60. Lain, S.; Hollick, J.J.; Campbell, J.; Staples, O.D.; Higgins, M.; Aoubala, M.; McCarthy, A.; Appleyard, V.; Murray, K.E.; Baker, L.; Thompson, A.; Mathers, J.; Holland, S.J.; Stark, M.J.; Pass, G.; Woods, J.; Lane, D.P.; Westwood, N.J. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell, 2008, 13, 454-463.
61. Brooks, C.L.; Gu, W. p53 Activation: a case against Sir. Cancer Cell, 2008, 13, 377-378.
62. Canto, C.; Auwerx, J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol. Metab., 2009, 20, 325-331.
63. Campisi, J.; Yaswen, P. Aging and cancer cell biology. Aging Cell, 2009, 8, 221-225.
64. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin., 2009, 59, 225-249.
65. Supiot, S.; Hill, R.P.; Bristow, R.G. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol. Cancer Ther., 2008, 7, 993-999.
66. Logan, I.R.; McNeill, H.V.; Cook, S.; Lu, X.; Lunec, J.; Robson, C.N. Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells. Prostate, 2007, 67, 900-906.
67. Lehmann, B.D.; McCubrey, J.A.; Jefferson, H.S.; Paine, M.S.; Chappell, W.H.; Terrian, D.M. A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle, 2007, 6, 595-605.
68. Shangary, S.; Ding, K.; Qiu, S.; Nikolovska-Coleska, Z.; Bauer, J.A.; Liu, M.; Wang, G.; Lu, Y.; McEachern, D.; Bernard, D.; Bradford, C.R.; Carey, T.E.; Wang, S. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol. Cancer Ther., 2008, 7, 1533-1542.
69. Saddler, C.; Ouillette, P.; Kujawski, L.; Shangary, S.; Talpaz, M.; Kaminski, M.; Erba, H.; Shedden, K.; Wang, S.; Malek, S.N. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood, 2008, 111, 1584-1593.
70. Secchiero, P.; Barbarotto, E.; Tiribelli, M.; Zerbinati, C.; di Iasio, M.G.; Gonelli, A.; Cavazzini, F.; Campioni, D.; Fanin, R.; Cuneo, A.; Zauli, G. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood, 2006, 107, 4122-4129.
71. Kojima, K.; Konopleva, M.; Samudio, I.J.; Shikami, M.; Cabreira-Hansen, M.; McQueen, T.; Ruvolo, V.; Tsao, T.; Zeng, Z.; Vassilev, L.T.; Andreeff, M. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood, 2005, 106, 3150-3159.
72. Coll-Mulet, L.; Iglesias-Serret, D.; Santidrian, A.F.; Cosialls, A.M.; de, F.M.; Castano, E.; Campas, C.; Barragan, M.; de Sevilla, A.F.; Domingo, A.; Vassilev, L.T.; Pons, G.; Gil, J. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood, 2006, 107, 4109-4114.
73. Stuhmer, T.; Bargou, R.C. Selective pharmacologic activation of the p53-dependent pathway as a therapeutic strategy for hematologic malignancies. Cell Cycle, 2006, 5, 39-42.
74. Stuhmer, T.; Chatterjee, M.; Hildebrandt, M.; Herrmann, P.; Gollasch, H.; Gerecke, C.; Theurich, S.; Cigliano, L.; Manz, R.A.; Daniel, P.T.; Bommert, K.; Vassilev, L.T.; Bargou, R.C. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood, 2005, 106, 3609-3617.
75. Mohammad, R.M.; Wu, J.; Azmi, A.S.; Aboukameel, A.; Sosin, A.; Wu, S.; Yang, D.; Wang, S.; Al-Katib, A.M. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol. Cancer, 2009, 8, 115.
76. Miyachi, M.; Kakazu, N.; Yagyu, S.; Katsumi, Y.; Tsubai-Shimizu, S.; Kikuchi, K.; Tsuchiya, K.; Iehara, T.; Hosoi, H. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin. Cancer Res., 2009, 15, 4077-4084.
77. Canner, J.A.; Sobo, M.; Ball, S.; Hutzen, B.; DeAngelis, S.; Willis, W.; Studebaker, A.W.; Ding, K.; Wang, S.; Yang, D.; Lin, J. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br. J. Cancer, 2009, 101, 774-781.
78. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin., 2009, 59, 225-249.
79. Custodio, A.; Puente, J.; Sastre, J.; az-Rubio, E. Second-line therapy for advanced pancreatic cancer: A review of the literature and future directions. Cancer Treat. Rev., 2009, 35(8), 676-684.
80. Burris, H.A., III; Rivkin, S.; Reynolds, R.; Harris, J.; Wax, A.; Gerstein, H.; Mettinger, K.L.; Staddon, A. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist, 2005, 10, 183-190.
81. Azmi, A.S.; Aboukameel, A.; Banerjee, S.; Wang, Z.; Mohammad, M.; Wu, J.; Wang, S.; Yang, D.; Philip, P.A.; Sarkar, F.H.; Mohammad, R.M. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur. J. Cancer, 2010, 46(6), 1122-1131.
82. Zhang, Z.; Zhang, R. p53-independent activities of MDM2 and their relevance to cancer therapy. Curr. Cancer Drug Targets., 2005, 5, 9-20.
83. Stommel, J.M.; Wahl, G.M. A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle, 2005, 4, 411-417.
84. Gu, W.; Luo, J.; Brooks, C.L.; Nikolaev, A.Y.; Li, M. Dynamics of the p53 acetylation pathway. Novartis Found. Symp., 2004, 259, 197-205.
85. Ito, A.; Kawaguchi, Y.; Lai, C.H.; Kovacs, J.J.; Higashimoto, Y.; Appella, E.; Yao, T.P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J., 2002, 21, 6236-645.
86. Hasegawa, K.; Yoshikawa, K. Necdin regulates p53 acetylation via Sirtuin1 to modulate DNA damage response in cortical neurons. J. Neurosci., 2008, 28, 8772-8784.
87. Choong, M.L.; Yang, H.; Lee, M.A.; Lane, D.P. Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle, 2009, 8, 2810-2818.